Therapeutic strategies for Alzheimer's disease based on new molecular mechanisms

Acta Neurobiologiae Experimentalis

Volumn 63, Issue 4, 2003, Pages 393-396

  Religa, Dorota ^a,b   Winblad, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Amyloid peptide; Homocysteine; Memantine; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HOMOCYSTEINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NEUROTROPHIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; STATINE; TACRINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; DEMENTIA; HUMAN; IMMUNIZATION; PROTEIN PROCESSING; SENILE PLAQUE; SHORT SURVEY; VACCINATION; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; AMYLOIDOSIS; CHOLINESTERASE INHIBITORS; HOMOCYSTEINE; HUMANS;

EID: 0345095292     PISSN: 00651400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., Teplow D.B. (2003) Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100: 330-335.
2. Crisby M., Carlson L.A., Winblad B. (2002) Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 16: 131-136.
3. Czyzewski K., Lalowski M.M., Pfeffer A., Barcikowska M. (2001) Lipid metabolism parameters in patients with Alzheimer's disease and their first degree relatives. Acta Neurobiol Exp 61: 21-26.
4. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von Bergmann K., Lutjohann D. (2002) Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59: 1257-1258.
5. Jelic V., Winblad B. (2003) Treatment strategies in Alzheimer's Disease. Brain Aging 2: 20-23.
6. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. (2003) Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60: 203-208.
7. Religa D., Styczynska M., Peplonska B., Gabryelewicz T., Pfeffer A., Chodakowska M., Stepien K., Luczywek E., Wasiak B., Golebiewski M., Winblad B., Barcikowska M. (2003) Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 16: 64-70.
8. Selkoe D.J., (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399 (suppl): A23-31.
9. Trinh N.H., Hoblyn J., Mohanty S., Yaffe K. (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289: 210-216.
10. Tuszynski M.H. (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1: 51-57.
11. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golge T.E., Koo E.H. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216.
12. Winblad B., Poritis N. (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14: 135-146.